Literature DB >> 1964448

Absorption, disposition and preliminary metabolic pathway of 14C-rifabutin in animals and man.

R Battaglia1, E Pianezzola, G Salgarollo, G Zini, M Strolin Benedetti.   

Abstract

14C-Rifabutin was given orally to rats, rabbits and monkeys at a dose of 25 mg/kg and to healthy volunteers at a dose of 270 mg. Radioactivity was eliminated by both the renal and faecal routes in all species, with a predominance of the renal route in man and monkeys (50.19% and 46.73% of the dose, respectively, in urine at 96 h), whereas in rats and rabbits a slight predominance of faecal excretion was observed (48.09% and 45.01% of the dose, respectively, at 96 h in faeces; 42.22% and 36.37% in urine). Radioactivity as expired 14CO2 was detected in the rat and accounted for less than 0.5% of the dose within 96 h. The drug was rapidly absorbed and peak plasma radioactivity levels were reached from 1 to 4 h after dosing. Rifabutin was the predominant compound circulating in plasma at the first sampling times, but significant levels of 31-OH rifabutin were detected up to 8-24 h in all species studied. 25-O-deacetyl rifabutin was detected only in rat and man. Polar metabolites were also present, particularly at the later sampling times. The urinary metabolism was studied by radio-HPLC. Rifabutin accounted for 8.5% and 4.6% of the dose in 0-24 h urine of rats and man respectively, whereas in rabbit and monkey urine only traces of this compound were detected. The main known metabolite in all animal species was 31-OH rifabutin; 25-O-deacetyl rifabutin was detected only in rat and man. The remaining urinary radioactivity was mainly due to polar compounds.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1964448     DOI: 10.1093/jac/26.6.813

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

Review 1.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex.

Authors:  R C Li; S Nightingale; R C Lewis; D C Colborn; P K Narang
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients.

Authors:  Grant Langdon; Justin Wilkins; Lynn McFadyen; Helen McIlleron; Peter Smith; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

4.  Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients.

Authors:  R C Li; P K Narang; J Sahai; W Cameron; J R Bianchine
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

Review 5.  A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment.

Authors:  Russell R Kempker; Wael A Alghamdi; Mohammad H Al-Shaer; Gena Burch; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

6.  Absorption, disposition, and urinary metabolism of 14C-rifabutin in rats.

Authors:  R Battaglia; G Salgarollo; G Zini; L Montesanti; M Strolin Benedetti
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

7.  Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine.

Authors:  S T Brown; F F Edwards; E M Bernard; W Tong; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

8.  Single-dose pharmacokinetics of rifapentine in women.

Authors:  A C Keung; M G Eller; S J Weir
Journal:  J Pharmacokinet Biopharm       Date:  1998-02

Review 9.  Clinical pharmacokinetics of rifabutin.

Authors:  M H Skinner; T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

Review 10.  Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; A Fitton
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.